These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20116277)

  • 1. Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    Cytokine; 2010 May; 50(2):129-37. PubMed ID: 20116277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1.
    Breivik L; Oftedal BE; Bøe Wolff AS; Bratland E; Orlova EM; Husebye ES
    Clin Immunol; 2014 Jul; 153(1):220-7. PubMed ID: 24792136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum.
    Qiu ZJ; Ying Y; Fox M; Peng K; Lewin-Koh SC; Coleman D; Good J; Lowe J; Rahman A; Yang J; Jiang J; Quarmby V; Song A
    J Immunol Methods; 2010 Oct; 362(1-2):101-11. PubMed ID: 20868690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I.
    Oftedal BE; Wolff AS; Bratland E; Kämpe O; Perheentupa J; Myhre AG; Meager A; Purushothaman R; Ten S; Husebye ES
    Clin Immunol; 2008 Oct; 129(1):163-9. PubMed ID: 18708298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four distinct detection platforms using multiple ligand binding assay formats.
    Soderstrom CI; Spriggs FP; Song W; Burrell S
    J Immunol Methods; 2011 Aug; 371(1-2):106-13. PubMed ID: 21749873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing natural anti-IL-17F autoantibodies protect Autoimmune Polyendocrine Syndrome Type 1 (APS-1) patients from asthma.
    Jokinen M; Edelman S; Krohn K; Kankainen M; Ranki A
    Clin Immunol; 2020 Oct; 219():108512. PubMed ID: 32544610
    [No Abstract]   [Full Text] [Related]  

  • 8. Structure of IL-17A in complex with a potent, fully human neutralizing antibody.
    Gerhardt S; Abbott WM; Hargreaves D; Pauptit RA; Davies RA; Needham MR; Langham C; Barker W; Aziz A; Snow MJ; Dawson S; Welsh F; Wilkinson T; Vaugan T; Beste G; Bishop S; Popovic B; Rees G; Sleeman M; Tuske SJ; Coales SJ; Hamuro Y; Russell C
    J Mol Biol; 2009 Dec; 394(5):905-21. PubMed ID: 19835883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody.
    Liao K; Sikkema D; Wang C; Chen K; DeWall S; Lee TN
    J Immunol Methods; 2012 Jan; 375(1-2):258-63. PubMed ID: 22001556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins.
    Hu J; Wala I; Han H; Nagatani J; Barger T; Civoli F; Kaliyaperumal A; Zhuang Y; Gupta S
    J Immunol Methods; 2015 Apr; 419():1-8. PubMed ID: 25795420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
    Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A
    J Neuroimmunol; 2010 Mar; 220(1-2):114-9. PubMed ID: 20117845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells.
    Konishi E; Tabuchi Y; Yamanaka A
    J Virol Methods; 2010 Feb; 163(2):360-7. PubMed ID: 19883692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera.
    Shin SK; Ha SK; Lee KW; Yoo TH; Yun SR; Yoon SH; Kim SJ; Lee SK; Heo TH
    J Pharm Biomed Anal; 2010 Jun; 52(2):289-93. PubMed ID: 20133098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference.
    McCutcheon KM; Quarmby V; Song A
    J Immunol Methods; 2010 Jun; 358(1-2):35-45. PubMed ID: 20361968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A.
    Okiyama N; Sugihara T; Iwakura Y; Yokozeki H; Miyasaka N; Kohsaka H
    Arthritis Rheum; 2009 Aug; 60(8):2505-12. PubMed ID: 19644888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I.
    Puel A; Döffinger R; Natividad A; Chrabieh M; Barcenas-Morales G; Picard C; Cobat A; Ouachée-Chardin M; Toulon A; Bustamante J; Al-Muhsen S; Al-Owain M; Arkwright PD; Costigan C; McConnell V; Cant AJ; Abinun M; Polak M; Bougnères PF; Kumararatne D; Marodi L; Nahum A; Roifman C; Blanche S; Fischer A; Bodemer C; Abel L; Lilic D; Casanova JL
    J Exp Med; 2010 Feb; 207(2):291-7. PubMed ID: 20123958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay.
    Schwickart M; Mehrzai F; Pearson J; Shaghasi N; Chavez C; Schneider A; Wu S; Roskos L; Liang M
    J Immunol Methods; 2014 Jan; 403(1-2):52-61. PubMed ID: 24287421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved detection of cell surface proteins using an electrochemiluminescent cell-binding assay.
    Pang S; Ahsan ES; Foy CA
    J Immunol Methods; 2010 Oct; 362(1-2):176-9. PubMed ID: 20688072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.